Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.62), $0.12 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $2.7 million.

“2021 promises to be a pivotal year for Syros,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We moved our lead program into our first registration-enabling study and continue to advance all three of our clinical-stage programs with the aim of setting new standards of care for targeted populations of patients with hematological malignancies and solid tumors. Following our recent financings, we are operating from a position of substantial strength, with capital to advance SY-1425, SY-2101 and SY-5609 through multiple expected data readouts while investing in our gene control platform to fuel our long-term pipeline. We are focused on executing with excellence as we accelerate toward our goal of bringing medicines to market that provide profound benefits for patients.”

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Spotify (SPOT) jumps as Q1 print tops estimates on top and bottom lines
• JPMorgan is worried about further S&P 500 sell-off potential
• Hibbett (HIBB) soars 18% on deal to sell to JD Sports for $1.08 billion